Gilead Sciences jumps 16% as severe COVID-19 patients respond to its antiviral drug
- University of Chicago reports severe COVID-19 patients responding to Gilead's Remdesivir.
- Gilead has partnered with 152 locations for its study involving severe COVID-19 patients.
- U.S NIH also performed a Remdesivir trial including a control group in February 2020.
Gilead Sciences Inc. (NASDAQ: GILD) started human trials of its prospect antiviral, Remdesivir, recently in critical cases of COVID-19. As per a media report on Thursday, patients were reported to have been responding well to the experimental drug. Following the report, Gilead was seen 16% up in extended trading on Thursday.
More industry news
Will tariffs really bring manufacturing back to the US?
April 16, 2025
Raydium’s token launch tool goes live, challenges Pump.fun
April 16, 2025
